Bristol-Myers Squibb Company Stock (US0897961004): Q1 Revenues Rise 3% to $11.5 Billion

Bristol Myers Squibb reported first quarter 2026 revenues of $11.5 billion, up 3% from prior year, driven by 12% growth in its Growth Portfolio to $6.2 billion including Camzyos, Breyanzi and Reblozyl, according to company press release.

Bristol Myers Squibb reported first quarter 2026 financial results on April 30, 2026, with revenues reaching $11.5 billion, an increase of 3% on a reported basis and 1% excluding foreign exchange effects from the prior year period, according to company press release dated 04/30/2026. The Growth Portfolio, comprising newer products, generated $6.2 billion in revenues, up 12% reported and 9% ex-FX, primarily driven by strong performances from Camzyos, Breyanzi and Reblozyl.

As of: April 30, 2026

By the AD HOC NEWS Editorial Team – Equity Coverage.

At a Glance

• Name: Bristol Myers Squibb
• ISIN: US0897961004
• Sector/Industry: Healthcare / Biopharmaceuticals
• Headquarters/Country: New York / United States
• Primary Exchange: NYSE
• Trading Currency: USD
• Last Quarterly Results: Q1 2026 revenues $11.5 billion, published 04/30/2026

How Bristol-Myers Squibb Company Makes Money: The Core Business Model

Bristol-Myers Squibb Company develops, manufactures and markets biopharmaceutical products for serious diseases including cancer, cardiovascular conditions and immunology disorders. The company generates revenues primarily through sales of patented drugs to healthcare providers, pharmacies and government programs in the United States and international markets. In the first quarter of 2026, total revenues reached $11.5 billion, according to company press release dated 04/30/2026.

The business model relies on a portfolio of blockbuster drugs, with the Growth Portfolio contributing $6.2 billion or over half of quarterly revenues, up 12% year-over-year. Legacy products provide stable cash flows while newer therapies drive expansion into high-growth areas like cell therapy and rare diseases. Research and development investments support a pipeline of over 50 programs targeting oncology and cardiovascular improvements.

Manufacturing occurs at facilities in the United States, Europe and Asia, with distribution through partnerships and direct sales forces. The company reported first quarter 2026 profit of $2.68 billion, or $1.31 per share, compared to $2.46 billion, or $1.20 per share in the year-ago quarter, according to permitted secondary reporting on the results publication date of 04/30/2026.

Bristol-Myers Squibb Company's Key Revenue and Product Drivers

The Growth Portfolio led revenue expansion in first quarter 2026 with $6.2 billion, a 12% increase driven by volume growth in cardiovascular therapy Camzyos, cell therapy Breyanzi and hematology drug Reblozyl, according to company press release dated 04/30/2026. These products target underserved patient populations in heart failure, lymphoma and anemia.

Overall revenues of $11.5 billion reflected 3% growth, with the Growth Portfolio offsetting declines in mature brands. Eliquis, a leading anticoagulant co-marketed with Pfizer, remains a major contributor alongside Opdivo in oncology. Recent initiatives include making Eliquis available via Mark Cuban Cost Plus Drug Company to improve access, announced in April 2026.

Pipeline advancements support future revenue potential, with recent regulatory approvals expanding labels for existing therapies. First quarter results underscore the strategy of balancing legacy cash generation with growth from innovative medicines.

Industry Trends and Competitive Landscape

The biopharmaceutical sector faces patent cliffs on blockbuster drugs, prompting investment in next-generation therapies like cell and gene treatments. Bristol-Myers Squibb competes with peers such as Pfizer, Merck & Co. and Regeneron Pharmaceuticals in oncology and immunology, all verifiable through their respective 10-K filings as participants in similar therapeutic segments.

Cardiovascular remains a key growth area amid rising chronic disease prevalence, with competitors including Novartis and AstraZeneca offering rival heart failure and anticoagulant options. Hematology markets see competition from companies like Incyte and bluebird bio in anemia and cell therapy applications.

Overall industry revenues grow through pipeline innovation, with biopharma firms prioritizing rare diseases and precision medicine to sustain margins post-patent expiry.

Why Bristol-Myers Squibb Company Matters to US Investors

Bristol-Myers Squibb trades on the New York Stock Exchange under ticker BMY in US dollars, providing direct exposure for US investors to biopharmaceutical innovation. The company files regular reports with the US Securities and Exchange Commission, including the first quarter 2026 results announced on 04/30/2026 showing $11.5 billion revenues.

With significant US revenue from Medicare, Medicaid and private insurers, the firm benefits from the large American healthcare market. NYSE listing ensures liquidity and transparency for institutional and retail participants tracking S&P 500 healthcare constituents.

Denominated in USD, shares avoid direct foreign exchange risk, appealing to US portfolios focused on domestic-listed global pharma leaders.

Which Investor Profile Fits Bristol-Myers Squibb Company – and Which Does Not?

Investors interested in biopharmaceutical firms with established blockbusters transitioning to growth products may monitor Bristol-Myers Squibb, given its Q1 2026 revenue mix of $11.5 billion total and $6.2 billion from newer therapies. Those tracking NYSE-listed healthcare names with SEC oversight find alignment with the company's structure.

Participants avoiding early-stage biotech volatility might note the blend of mature and pipeline-driven revenues. Profiles seeking pure-play rare disease or gene therapy exposure could look elsewhere, as the portfolio spans multiple therapeutic areas.

Diversified equity holders balancing growth and dividend potential often include large-cap pharma like this NYSE-listed entity.

Risks and Open Questions for Bristol-Myers Squibb Company

Patent expirations on key drugs like Eliquis pose revenue risks as generics enter markets, potentially impacting future quarters beyond Q1 2026 results. Pipeline success rates remain uncertain, with clinical trial outcomes affecting long-term growth.

Regulatory approvals from the US FDA carry scrutiny for new indications, while pricing pressures from US government programs influence margins. Manufacturing scale-up for cell therapies like Breyanzi presents supply chain challenges.

Competition intensifies across oncology and cardiovascular segments, requiring sustained R&D to maintain market positions.

Key Events and Outlook for Investors

Following Q1 2026 results reported on April 30, 2026, investor focus shifts to subsequent quarterly updates and pipeline milestones. The company maintains guidance for the year, though specific ranges were outlined in the earnings materials.

Upcoming events include potential second quarter reporting in July 2026 and ongoing regulatory submissions for pipeline candidates.

What to Watch Next

• Q2 2026: Expected quarterly results reporting
• Pipeline Updates: FDA decisions on key therapies

Conclusion

Bristol Myers Squibb's first quarter 2026 results highlighted revenue growth to $11.5 billion, propelled by the Growth Portfolio's 12% rise to $6.2 billion as detailed in the April 30, 2026 press release. This performance reflects execution on newer products amid legacy portfolio dynamics. US investors continue tracking the NYSE-listed stock for updates on pipeline progress and quarterly financials.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.